抗NuMA抗体在原发性干燥综合征与系统性红斑狼疮中的临床关联及意义
该研究在2013至2018年间比较了抗NuMA抗体阳性的pSS和SLE患者与抗体阴性队列的临床及免疫学特征。抗NuMA抗体罕见(占ANA阳性血清0.29%),主要见于pSS和SLE,且阳性患者临床表现和生物学指标较轻,提示其可能为良好预后标志物。
要点
- 抗NuMA抗体罕见,在ANA阳性血清中占0.29%,主要与pSS和SLE相关。
- 抗NuMA阳性pSS患者眼干、干燥并发症及抗SSa/SSb抗体更少。
- 抗NuMA阳性SLE患者无狼疮肾炎,抗dsDNA抗体和补体消耗更少。
核心结论
- 抗NuMA抗体虽罕见,但主要与pSS和SLE相关,在其他自身抗体阴性时可能有助于诊断。
- 抗NuMA阳性的pSS和SLE患者临床和生物学表现较轻,提示该抗体可能是两种疾病的良好预后标志物。
研究设计与样本
- 2013至2018年间,比较抗NuMA抗体阳性的pSS和SLE患者与抗NuMA抗体阴性pSS和SLE队列的临床和免疫学特征。
主要发现
- 67.8%的抗NuMA抗体阳性患者患有自身免疫病,主要为pSS(28.9%)和SLE(21.1%)。
- 抗NuMA抗体是60%的pSS患者和50%的SLE患者中唯一的ANA。
- 与137例抗NuMA阴性pSS患者相比,20例抗NuMA阳性pSS患者眼干综合征(70.0% vs 89.1%,P=0.031)、干燥并发症(15.0% vs 39.4%,P=0.045)及可检测到的抗SSa和/或抗SSb抗体(40.0% vs 66.4%,P=0.027)更少。
- 与80例抗NuMA阴性SLE患者相比,14例抗NuMA阳性SLE患者无狼疮肾炎(0.0% vs 28.8%,P=0.049),抗dsDNA抗体(42.9% vs 75.0%,P=0.025)和补体消耗(21.4% vs 53.8%,P=0.040)更少。
- 抗NuMA阳性的pSS和SLE患者较抗NuMA阴性患者更少需要治疗。
临床怎么用
- 对于其他自身抗体阴性的疑似pSS或SLE患者,抗NuMA抗体检测可能有助于诊断。
- 抗NuMA抗体阳性可能提示pSS和SLE临床表型较轻、预后较好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the clinical significance of anti-nuclear mitotic apparatus (NuMA) antibodies (AC-26 or AC-25) in patients with primary Sjögren's syndrome (pSS) and SLE. METHODS: Between 2013 and 2018, clinical and immunological features of pSS and SLE patients with anti-NuMA antibodies were compared with anti-NuMA antibodies-negative pSS and SLE cohorts. RESULTS: Among 31 284 sera positive for antinuclear antibodies, 90 patients (0.29%) had anti-AC-26 (anti-NuMA1) and AC-25 (anti-HsEg5) antibodies (73.3% and 26.7%, respectively). Autoimmune diseases, mainly consisting in pSS (28.9%) and SLE (21.1%), were found in 67.8%. Anti-NuMA antibodies represented the unique ANA in 60% and 50% of patients with pSS and SLE patients, respectively. Compared with 137 anti-NuMA-negative pSS patients, 20 anti-NuMA-positive pSS presented with less frequent ocular sicca syndrome (70.0% vs 89.1%, P=0.031), dryness complications (15.0% vs 39.4%, P=0.045), or detectable anti-SSa and/or anti-SSb antibodies (40.0% vs 66.4%, P=0.027). Compared with 80 anti-NuMA-negative SLE patients, 14 anti-NuMA-positive SLE patients had no lupus nephritis (0.0% vs 28.8%, P=0.049), less frequent dsDNA antibodies (42.9% vs 75.0%, P=0.025) and complement consumption (21.4% vs 53.8%, P=0.040). Anti-NuMA-positive pSS and SLE patients less frequently required treatments compared with anti-NuMA-negative patients. CONCLUSION: Although rare, anti-NuMA antibodies are mainly associated with pSS and SLE and may be useful for diagnosis when other auto-antibodies are negative. PSS and SLE patients with anti-NuMA antibodies have less severe clinical and biological profiles, suggesting that anti-NuMA antibodies may constitute a good prognosis marker in both autoimmune diseases.
引用
- Arcani R, Bertin D, Bardin N, et al. Anti-NuMA antibodies: clinical associations and significance in patients with primary Sjögren's syndrome or systemic lupus erythematosus. Rheumatology (Oxford). 2021. PMID: 33404653. doi:10.1093/rheumatology/keaa881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。